Abstract
Introduction: The pandemic COVID-19 viral infection is a global threat with a high mortality, mainly due to acute respiratory distress syndrome and respiratory failure (ARDS). Some of these patients develop radiological pulmonary fibrotic signs after just few weeks of hospitalization.
Objectives: To evaluate those ARDS-COVID19 patients at intensive care unit (ICU) that present low-compliance, ventilatory difficulties and fibrotic signs at the chest HRCT, including safety profile of anti-fibrotic use.
Methods: observational retrospective study of hospitalized patients that required intensive care and were registered as ARDS-COVID19 complicated with pulmonary fibrotic radiological and physiological signs from March to July 2020.
Results: From a total of388patients that required ventilatory support since ARDS-COVID19, 28 were included. The mean age was 56.32 ± 11.23 years. All patients presented severe respiratory failure with a median SaFi (Sa02/Fi02) 282.9% (IQR 284.47%). 27 patients required intubation and mechanical ventilation. Fibrotic signs on chest HRCT were identified at 39.6 days (SD 19.72) from admission; and all received corticosteroid treatment. 11 patients received pirfenidone. Mortality rate was 21.43% and was similar between groups, although patients that were treated with pirfenidone showed lower SaFi at hospitalization, more days of mechanical ventilation and tracheostomy. No severe adverse events associated to pirfenidone medication were observed.
Conclusions: Pulmonary fibrotic changes after ARDS-Covid-19 at ICU present a high in-hospital mortality. Anti-fibrotic medication present a safety profile in these patients.
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA2537.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021